	US 12,241,100 B2
	Engineered leucine decarboxylases
Joyce Liu, Fremont, CA (US); Leann Quertinmont Teadt, Redwood City, CA (US); Nikki Dellas, San Carlos, CA (US); Stephan Jenne, Foster City, CA (US); Faye Loan Du, San Jose, CA (US); Kristen Jean Vallieu, Union City, CA (US); and Kerryn McCluskie, Pacifica, CA (US)
Assigned to SYNTIS BIO, INC., Boston, MA (US)
Filed by Syntis Bio, Inc., Boston, MA (US)
Filed on Feb. 3, 2021, as Appl. No. 17/166,934.
Claims priority of provisional application 62/970,039, filed on Feb. 4, 2020.
Prior Publication US 2021/0238575 A1, Aug. 5, 2021
Int. Cl. C12N 9/88 (2006.01); A61K 38/00 (2006.01)

CPC C12N 9/88 (2013.01) [A61K 38/00 (2013.01); C12Y 401/01014 (2013.01)]

6 Claims

1. An engineered leucine decarboxylase polypeptide comprising an amino acid sequence having at least 90%, 91%, 92,%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to the entire sequence set forth in SEQ ID NO: 12, wherein the amino acid positions of said amino acid sequence are numbered with reference to the amino acid sequence of SEQ ID NO: 12, and wherein said amino acid sequence comprises a substitution at position 364, selected from L364K and L364R.